Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00856180 · ClinicalTrials.gov registry record · Phase 2
Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian Malignancies
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT00856180 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 20 participants.
The verdict
NCT00856180, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The goals of this study were to evaluate the efficacy and safety of sequentially blocking the angiogenesis pathway via known antiangiogenic mechanisms, first with bevacizumab and then addition of oral cyclophosphamide upon progression of cancer through bevacizumab. The drugs used in this study were chosen because of their known antiangiogenic properties, tolerability, and anti-ovarian cancer effects.
Interventions
- DRUG Cyclophosphamide
- DRUG Bevacizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2009-02 |
| Est. Completion | 2014-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00856180
The ClinicalTrials.gov registry entry for NCT00856180 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cyclophosphamide is the first listed.
NCT00856180 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00856180 about?
NCT00856180 is a clinical study titled "Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian Malignancies". The goals of this study were to evaluate the efficacy and safety of sequentially blocking the angiogenesis pathway via known antiangiogenic mechanisms, first with bevacizumab and then addition of oral cyclophosphamide upon progression of cancer through bevacizumab. The drugs used in this study were ...
What is the current status of trial NCT00856180?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2009-02. Estimated completion is 2014-01.
What interventions are being tested in trial NCT00856180?
The interventions under investigation include: Cyclophosphamide (DRUG), Bevacizumab (DRUG).
Who is sponsoring clinical trial NCT00856180?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.